Neuro-oncology, a decade of temozolomide and beyond

Expert Review of Anticancer Therapy

Volumn 10, Issue 11, 2010, Pages 1675-1677

  Stupp, Roger ^a   Hegi, Monika ^a   Weller, Michael ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

bevacizumab; clinical trials; glioma; MGMT; molecular markers; new agents; temozolomide

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CILENGITIDE; ENZASTAURIN; ERLOTINIB; LOMUSTINE; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG TOLERABILITY; EDITORIAL; GLIOBLASTOMA; HUMAN; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DACARBAZINE; HUMANS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 78649248682     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.161     Document Type: Editorial

References (16)

1. Yung WK, Prados MD, Yaya-Tur R et al. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762-2771 (1999).
2. Yung WK, Albright RE, Olson J et al. A Phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588-593 (2000).
3. Brada M, Hoang-Xuang K, Rampling R et al. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol. 12, 259-266 (2001).
4. Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of temozolomide in the treatment of brain tumors. Lancet Oncol. 2, 552-560 (2001).
5. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996 (2005).
6. Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised Phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 10, 459-466 (2009).
7. Wick W, Hartmann C, Engel C et al. NOA-04 randomized Phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874-5880 (2009).
8. Hegi ME, Diserens AC, Gorlia T et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005).
9. Weller M, Stupp R, Reifenberger G et al. MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat. Rev. Neurol. 6, 39-51 (2010).
10. Vredenburgh JJ, Desjardins A, Herndon JE 2nd et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol. 25, 4722-4729 (2007).
11. Friedman HS, Prados MD, Wen PY et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733-4740 (2009).
12. Stupp R, Hegi ME, Neyns B et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718 (2010).
13. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J. Clin. Oncol. 28, 1168-1174 (2010).
14. van den Bent M, Brandes A, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma. Report from EORTC Brain Tumor Group study 26034. J. Clin. Oncol. 27, 1268-1274 (2009).
15. Thiel E, Korfel A, Martus P et al. Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized Phase IV trial. J. Clin. Oncol. 28 (Suppl. 15) (2010) (Abstract 8008).
16. Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with Hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med. 361, 1173-1178 (2009).